Literature DB >> 27681596

Small Molecule Inhibition of the Ubiquitin-specific Protease USP2 Accelerates cyclin D1 Degradation and Leads to Cell Cycle Arrest in Colorectal Cancer and Mantle Cell Lymphoma Models.

Mindy I Davis1, Rajan Pragani1, Jennifer T Fox1, Min Shen1, Kalindi Parmar2, Emily F Gaudiano2, Li Liu1, Cordelle Tanega1, Lauren McGee1, Matthew D Hall1, Crystal McKnight1, Paul Shinn1, Henrike Nelson1, Debasish Chattopadhyay3, Alan D D'Andrea2, Douglas S Auld1, Larry J DeLucas3, Zhuyin Li1, Matthew B Boxer4, Anton Simeonov5.   

Abstract

Deubiquitinases are important components of the protein degradation regulatory network. We report the discovery of ML364, a small molecule inhibitor of the deubiquitinase USP2 and its use to interrogate the biology of USP2 and its putative substrate cyclin D1. ML364 has an IC50 of 1.1 μm in a biochemical assay using an internally quenched fluorescent di-ubiquitin substrate. Direct binding of ML364 to USP2 was demonstrated using microscale thermophoresis. ML364 induced an increase in cellular cyclin D1 degradation and caused cell cycle arrest as shown in Western blottings and flow cytometry assays utilizing both Mino and HCT116 cancer cell lines. ML364, and not the inactive analog 2, was antiproliferative in cancer cell lines. Consistent with the role of cyclin D1 in DNA damage response, ML364 also caused a decrease in homologous recombination-mediated DNA repair. These effects by a small molecule inhibitor support a key role for USP2 as a regulator of cell cycle, DNA repair, and tumor cell growth.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  USP2; cancer biology; cell cycle; cyclin D1; drug discovery; enzyme inhibitor; ubiquitin-dependent protease; ubiquitylation (ubiquitination)

Mesh:

Substances:

Year:  2016        PMID: 27681596      PMCID: PMC5114414          DOI: 10.1074/jbc.M116.738567

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

1.  Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization.

Authors:  J Y Li; F Gaillard; A Moreau; J L Harousseau; C Laboisse; N Milpied; R Bataille; H Avet-Loiseau
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

2.  USP2a protein deubiquitinates and stabilizes the circadian protein CRY1 in response to inflammatory signals.

Authors:  Xin Tong; Katie Buelow; Anirvan Guha; Rebecca Rausch; Lei Yin
Journal:  J Biol Chem       Date:  2012-06-05       Impact factor: 5.157

3.  High throughput microsomal stability assay for insoluble compounds.

Authors:  Li Di; Edward H Kerns; Susan Q Li; Susan L Petusky
Journal:  Int J Pharm       Date:  2006-03-17       Impact factor: 5.875

4.  Compound Management for Quantitative High-Throughput Screening.

Authors:  Adam Yasgar; Paul Shinn; Ajit Jadhav; Douglas Auld; Sam Michael; Wei Zheng; Christopher P Austin; James Inglese; Anton Simeonov
Journal:  JALA Charlottesv Va       Date:  2008-04

5.  A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers.

Authors:  Siwanon Jirawatnotai; Yiduo Hu; Wojciech Michowski; Joshua E Elias; Lisa Becks; Frederic Bienvenu; Agnieszka Zagozdzon; Tapasree Goswami; Yaoyu E Wang; Alan B Clark; Thomas A Kunkel; Tanja van Harn; Bing Xia; Mick Correll; John Quackenbush; David M Livingston; Steven P Gygi; Piotr Sicinski
Journal:  Nature       Date:  2011-06-08       Impact factor: 49.962

6.  The isopeptidase USP2a protects human prostate cancer from apoptosis.

Authors:  Carmen Priolo; Dan Tang; Mohan Brahamandan; Barbara Benassi; Ewa Sicinska; Shuji Ogino; Antonella Farsetti; Alessandro Porrello; Stephen Finn; Johann Zimmermann; Phillip Febbo; Massimo Loda
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

7.  A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein.

Authors:  V Chau; J W Tobias; A Bachmair; D Marriott; D J Ecker; D K Gonda; A Varshavsky
Journal:  Science       Date:  1989-03-24       Impact factor: 47.728

Review 8.  Development of the proteasome inhibitor Velcade (Bortezomib).

Authors:  Julian Adams; Michael Kauffman
Journal:  Cancer Invest       Date:  2004       Impact factor: 2.176

9.  The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer.

Authors:  Edgard Graner; Dan Tang; Sabrina Rossi; Antonella Baron; Toshiro Migita; Lisa J Weinstein; Mirna Lechpammer; Dieter Huesken; Johann Zimmermann; Sabina Signoretti; Massimo Loda
Journal:  Cancer Cell       Date:  2004-03       Impact factor: 31.743

Review 10.  The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention.

Authors:  John P Alao
Journal:  Mol Cancer       Date:  2007-04-02       Impact factor: 27.401

View more
  47 in total

1.  Correcting errors in the BRCA1 warning system.

Authors:  Yanping Liang; William J Dearnaley; Nick A Alden; Maria J Solares; Brian L Gilmore; Kevin J Pridham; A Cameron Varano; Zhi Sheng; Elizabeth Alli; Deborah F Kelly
Journal:  DNA Repair (Amst)       Date:  2018-11-22

2.  USP1 Is Required for Replication Fork Protection in BRCA1-Deficient Tumors.

Authors:  Kah Suan Lim; Heng Li; Emma A Roberts; Emily F Gaudiano; Connor Clairmont; Larissa Alina Sambel; Karthikeyan Ponnienselvan; Jessica C Liu; Chunyu Yang; David Kozono; Kalindi Parmar; Timur Yusufzai; Ning Zheng; Alan D D'Andrea
Journal:  Mol Cell       Date:  2018-12-20       Impact factor: 17.970

Review 3.  Deubiquitinases: Pro-oncogenic Activity and Therapeutic Targeting in Blood Malignancies.

Authors:  Blanca T Gutierrez-Diaz; Wei Gu; Panagiotis Ntziachristos
Journal:  Trends Immunol       Date:  2020-03-02       Impact factor: 16.687

Review 4.  Cyclin D degradation by E3 ligases in cancer progression and treatment.

Authors:  Shuo Qie; J Alan Diehl
Journal:  Semin Cancer Biol       Date:  2020-01-30       Impact factor: 15.707

5.  Downregulation of USP32 inhibits cell proliferation, migration and invasion in human small cell lung cancer.

Authors:  Wenyu Hu; Haiyan Wei; Keming Li; Pei Li; Jiamao Lin; Rui Feng
Journal:  Cell Prolif       Date:  2017-06-09       Impact factor: 6.831

6.  An integrative pan-cancer analysis of biological and clinical impacts underlying ubiquitin-specific-processing proteases.

Authors:  Di Chen; Zhen Ning; Huan Chen; Chang Lu; Xiaolong Liu; Tian Xia; Huan Qi; Wen Wang; Ting Ling; Xin Guo; Dinesh Singh Tekcham; Xiumei Liu; Jing Liu; Aman Wang; Qiu Yan; Ji-Wei Liu; Guang Tan; Hai-Long Piao
Journal:  Oncogene       Date:  2019-09-11       Impact factor: 9.867

7.  Ubiquitin-specific peptidase 2a (USP2a) deubiquitinates and stabilizes β-catenin.

Authors:  Jongchan Kim; Fatemeh Alavi Naini; Yutong Sun; Li Ma
Journal:  Am J Cancer Res       Date:  2018-09-01       Impact factor: 6.166

Review 8.  TGF-β signaling pathway mediated by deubiquitinating enzymes.

Authors:  Soo-Yeon Kim; Kwang-Hyun Baek
Journal:  Cell Mol Life Sci       Date:  2018-10-22       Impact factor: 9.261

Review 9.  The role of deubiquitinating enzymes in cancer drug resistance.

Authors:  Parthasaradhireddy Tanguturi; Kye-Seong Kim; Suresh Ramakrishna
Journal:  Cancer Chemother Pharmacol       Date:  2020-03-07       Impact factor: 3.333

Review 10.  The double dealing of cyclin D1.

Authors:  Guergana Tchakarska; Brigitte Sola
Journal:  Cell Cycle       Date:  2019-12-29       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.